 | • レポートコード：MRC2111A061 • 出版社/出版日：Transparency Market Research / 2021年10月30日 • レポート形態：英文、PDF、156ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、網膜静脈閉塞症の世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（網膜中心静脈閉塞症、網膜静脈分枝閉塞症）分析、治療タイプ別分析、地域別（北米、ヨーロッパ、アジア、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・網膜静脈閉塞症の世界市場規模：種類別（網膜中心静脈閉塞症、網膜静脈分枝閉塞症） ・網膜静脈閉塞症の世界市場規模：治療タイプ別 ・網膜静脈閉塞症の世界市場規模：地域別（北米、ヨーロッパ、アジア、中南米、中東・アフリカ） ・競争状況 |
Retinal Vein Occlusion Market – Scope of Report
TMR’s report on the global retinal vein occlusion market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the global retinal vein occlusion market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global retinal vein occlusion market for the forecast period.
The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global retinal vein occlusion market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the global retinal vein occlusion market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global retinal vein occlusion market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global retinal vein occlusion market. The next section of the global retinal vein occlusion market report highlights the USPs such as COVID-19 pandemic impact on industry (value chain and short/mid/long-term impact), regulatory scenario by region/globally, key industry events, and key success factors of top players operating in the global retinal vein occlusion market.
The report also delves into the competition landscape of the global retinal vein occlusion market. Key players operating in the global retinal vein occlusion market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, strategic overview, and SWOT are some of the attributes of players in the global retinal vein occlusion market profiled in this report.
Key Questions Answered in Retinal Vein Occlusion Market Report
What are the major drivers, restraints, and opportunities in the market?
What are the revenue share projections of key segments of the global retinal vein occlusion market during the forecast period?
Which segment is likely to lead the global retinal vein occlusion market in terms of revenue by 2031?
How technological developments are widening the scope for the global retinal vein occlusion market?
What is the market position of different companies operating in the global retinal vein occlusion market?
Retinal Vein Occlusion Market – Research Objectives and Research Approach
The comprehensive report on the global retinal vein occlusion market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind the study and health care compliances laid down by accredited agencies in the purview of research in the global retinal vein occlusion market. It is followed by market introduction, market dynamics, and an overview of the global retinal vein occlusion market, which includes TMR analysis of market drivers, restraints, and opportunities affecting the growth of the global retinal vein occlusion market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the global retinal vein occlusion market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global retinal vein occlusion market in terms of type, treatment type, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investments in the retinal vein occlusion market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Retinal Vein Occlusion Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Retinal Vein Occlusion Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. COVID-19 Pandemic Impact on Industry (value chain and short-/ mid-/ long-term impact)
6. Global Retinal Vein Occlusion Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast by Type, 2017–2031
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Market Attractiveness Analysis, by Type
7. Global Retinal Vein Occlusion Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment Type, 2017–2031
7.3.1. Anti-VEGF Drugs
7.3.2. Corticosteroid Drugs
7.3.3. Pan-retinal Photocoagulation Therapy
7.3.4. Laser Therapy
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Retinal Vein Occlusion Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Sub-region/Region
9. North America Retinal Vein Occlusion Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2031
9.2.1. Central Retinal Vein Occlusion
9.2.2. Branch Retinal Vein Occlusion
9.3. Market Value Forecast, by Treatment Type, 2017–2031
9.3.1. Anti-VEGF Drugs
9.3.2. Corticosteroid Drugs
9.3.3. Pan-retinal Photocoagulation Therapy
9.3.4. Laser Therapy
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment Type
9.5.3. By Country
10. Europe Retinal Vein Occlusion Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Central Retinal Vein Occlusion
10.2.2. Branch Retinal Vein Occlusion
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Anti-VEGF Drugs
10.3.2. Corticosteroid Drugs
10.3.3. Pan-retinal Photocoagulation Therapy
10.3.4. Laser Therapy
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment Type
10.5.3. By Country/Sub-region
11. Asia Retinal Vein Occlusion Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Central Retinal Vein Occlusion
11.2.2. Branch Retinal Vein Occlusion
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Anti-VEGF Drugs
11.3.2. Corticosteroid Drugs
11.3.3. Pan-retinal Photocoagulation Therapy
11.3.4. Laser Therapy
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment Type
11.5.3. By Country/Sub-region
12. Latin America Retinal Vein Occlusion Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Central Retinal Vein Occlusion
12.2.2. Branch Retinal Vein Occlusion
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Anti-VEGF Drugs
12.3.2. Corticosteroid Drugs
12.3.3. Pan-retinal Photocoagulation Therapy
12.3.4. Laser Therapy
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment Type
12.5.3. By Country/Sub-region
13. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Central Retinal Vein Occlusion
13.2.2. Branch Retinal Vein Occlusion
13.3. Market Value Forecast, by Treatment Type, 2017–2031
13.3.1. Anti-VEGF Drugs
13.3.2. Corticosteroid Drugs
13.3.3. Pan-retinal Photocoagulation Therapy
13.3.4. Laser Therapy
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment Type
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Alimera Sciences
14.3.1.1. Company Description
14.3.1.2. Business Overview
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Allergan (AbbVie, Inc.)
14.3.2.1. Company Description
14.3.2.2. Business Overview
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Annexin Pharmaceuticals AB (publ)
14.3.3.1. Company Description
14.3.3.2. Business Overview
14.3.3.3. Strategic Overview
14.3.3.4. SWOT Analysis
14.3.4. Bayer AG
14.3.4.1. Company Description
14.3.4.2. Business Overview
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Carl Zeiss AG
14.3.5.1. Company Description
14.3.5.2. Business Overview
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Description
14.3.6.2. Business Overview
14.3.6.3. Financial Overview
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Iridex Corporation
14.3.7.1. Company Description
14.3.7.2. Business Overview
14.3.7.3. Financial Overview
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Lumenis
14.3.8.1. Company Description
14.3.8.2. Business Overview
14.3.8.3. Strategic Overview
14.3.8.4. SWOT Analysis
14.3.9. Nidek Co., Ltd.
14.3.9.1. Company Description
14.3.9.2. Business Overview
14.3.9.3. Strategic Overview
14.3.9.4. SWOT Analysis
14.3.10. Novartis AG
14.3.10.1. Company Description
14.3.10.2. Business Overview
14.3.10.3. Financial Overview
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis
14.3.11. Regeneron Pharmaceuticals, Inc.
14.3.11.1. Company Description
14.3.11.2. Business Overview
14.3.11.3. Financial Overview
14.3.11.4. Strategic Overview
14.3.11.5. SWOT Analysis
14.3.12. Topcon Corporation
14.3.12.1. Company Description
14.3.12.2. Business Overview
14.3.12.3. Financial Overview
14.3.12.4. Strategic Overview
14.3.12.5. SWOT Analysis
Table 01: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 03: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 06: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 07: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 10: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 12: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 13: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 16: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031